RayzeBio
San Diego
About RayzeBio
RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Total funding: $418.0M
- Funding stage: M&A
- Last round: Series D (Sep 2022)
- Ticker: nasdaq:RYZB
- Website: rayzebio.com
- Phone: (858) 257-3421
Industries & Categories
Biotechnology, Health Care, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/rayzebio-20409 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.